End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
43.94 CNY | +2.16% | +1.83% | +9.74% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The company is in a robust financial situation considering its net cash and margin position.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 31.4 times its estimated earnings per share for the ongoing year.
- The company appears highly valued given the size of its balance sheet.
- The company is not the most generous with respect to shareholders' compensation.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+9.74% | 6.13B | C | ||
-33.59% | 15.3B | B- | ||
-25.32% | 11.07B | B | ||
-10.91% | 5.95B | C+ | ||
+0.88% | 4.79B | D- | ||
+53.60% | 4.36B | - | C | |
-10.49% | 3.69B | B | ||
-12.53% | 3.43B | C- | ||
-6.87% | 3.05B | C- | ||
-3.50% | 2.74B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 603939 Stock
- Ratings Yifeng Pharmacy Chain Co., Ltd.